Exclusion Criteria:~* Significant and/or current neurological disease affecting the central nervous system,
other than AD, that may affect cognition or ability to complete the study, including but not limited to, other
dementias, repetitive head trauma, serious infection of the brain, Parkinson's disease, epilepsy, or
cervicocranial vascular disease.~* Participants with any current primary psychiatric diagnosis other than AD
if, in the judgment of the investigator, the psychiatric disorder or symptom is likely to confound
interpretation of drug effect, affect cognitive assessment, or affect the participant's ability to complete the
study. Participants with history of schizophrenia or other chronic psychosis are excluded.~* Within 1 year
before the screening visit or between screening and randomization, any of the following: myocardial infarction;
moderate or severe congestive heart failure, New York Heart Association class III or IV; hospitalization for,
or symptoms of, unstable angina; syncope due to orthostatic hypotension or unexplained syncope; known
significant structural heart disease (such as, significant valvular disease, hypertrophic cardiomyopathy); or
hospitalization for arrhythmia.~* Congenital QT prolongation.~* Intermittent second- or third-degree
atrioventricular (AV) heart block or AV dissociation or history of ventricular tachycardia.~* A corrected QT
(QTcF) interval measurement >470 milliseconds (men and women) at screening (as determined at the
investigational site).~* History of malignant cancer within the last 5 years.~* History of vitiligo and/or
current evidence of post-inflammatory hypopigmentation.~* Calculated creatinine clearance <30 milliliters per
minute (Cockcroft-Gault formula; Cockcroft and Gault 1976) at screening.~* Currently enrolled in any other
clinical trial involving an investigational product or any other type of medical research judged not to be
scientifically or medically compatible with this study.
